| Age (years) |
60.5 ± 13.6 |
| Sex, Male/Female |
191/93 (67.3/32.7) |
| Body mass index (kg/cm2) |
21.4 ± 3.6 |
| Pre-stent Treatment |
|
| Surgery |
40 (14.1) |
| Radiotherapy |
33 (11.6) |
| Chemotherapy |
182 (64.1) |
| No further therapy |
29 (10.2) |
| Hydronephrosis, Bilateral/Unilateral |
63/221 (22.2/77.8) |
| Primary cancer |
|
| Gynecologic cancer |
64 (22.5) |
| Lung cancer |
10 (3.5) |
| Head and neck cancer |
1 (0.4) |
| Osteologic cancer |
2 (0.7) |
| Breast cancer |
15 (5.3) |
| Colorectal cancer |
70 (24.6) |
| Hepatobiliary cancer |
8 (2.8) |
| Stomach cancer |
105 (37.0) |
| Hematologic cancer |
5 (1.8) |
| Others |
4 (1.4) |
| Degree of hydronephrosis1/2/3/4 |
22/91/98/73 (7.8/32.0/34.5/25.7) |
| Patient’s ECOG 0/1/2/3 |
125/121/33/5 (44.0/42.6/11.6/1.8) |
| Serum Creatinine level before stenting |
1.5 ± 1.2 |
| sCr category (mg/dL) < 1.3 |
167 (58.8) |
| ≥ 1.31 |
117 (41.2) |
| Retrograde pyelography findings |
|
| Ureteral kinking shape |
|
| none/Z-shape/pigtail shape |
167/95/22 (58.8/33.5/7.7) |
| Irreversibility of ureteral kinking |
41 (14.4) |
| Ureteral direction, normal/lateralization |
264/20 (93.0/7.0) |
| Bladder invasion |
37 (13.0) |
| Stent duration (mean, months) |
8.6 ± 4.0 |
| Stenting failure |
40 (14.1) |
| Intra/postoperative stent failure |
10/30 (3.5/10.6) |
| Survival |
41 (14.4) |
| Overall Survival time (median, months) |
8.8 |
